{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:32:33Z","timestamp":1788543153346,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN0159928"],"award-info":[{"award-number":["FDN0159928"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-16-000131163"],"award-info":[{"award-number":["G-16-000131163"]}],"id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtha.2022.10.020","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T06:17:45Z","timestamp":1673158665000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in\u00a0vitro"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-9165","authenticated-orcid":false,"given":"Zeyu","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-3080","authenticated-orcid":false,"given":"Roxanna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-9254","authenticated-orcid":false,"given":"Rawaa H.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-6214","authenticated-orcid":false,"given":"Iqbal H.","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.10.020_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation-2014.1.306","article-title":"Central venous catheter-related thrombosis","volume":"2014","author":"Geerts","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2022.10.020_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.01.017","article-title":"Central venous catheter-related thrombosis in children and adults","volume":"187","author":"Citla Sridhar","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.020_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.actbio.2019.06.021","article-title":"The blood compatibility challenge. Part 1: blood-contacting medical devices: the scope of the problem","volume":"94","author":"Jaffer","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jtha.2022.10.020_bib4","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2022.10.020_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.07.002","article-title":"Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults","volume":"157","author":"Baumann Kreuziger","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.020_bib6","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/jth.15487","article-title":"Venous thromboembolism associated with central venous catheters in patients with cancer: from pathophysiology to thromboprophylaxis, areas for future studies","volume":"19","author":"Debourdeau","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.020_bib7","first-page":"CD006468","article-title":"Anticoagulation for people with cancer and central venous catheters","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2022.10.020_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1160\/TH07-07-0446","article-title":"Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis","volume":"99","author":"Chaukiyal","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.020_bib9","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2022.10.020_bib10","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.10.020_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2022.10.020_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.10.020_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.10.020_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.10.020_bib15","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in\u00a0vitro and in\u00a0vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.020_bib16","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.020_bib17","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jtha.2022.10.020_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in\u00a0vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.020_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A\u00a0universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.020_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ijlh.13692","article-title":"Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban","volume":"44","author":"von Horn","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2022.10.020_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1060028015578451","article-title":"Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?","volume":"49","author":"Gosselin","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2022.10.020_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2017.05.024","article-title":"Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels","volume":"156","author":"Sabor","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.020_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-Xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2022.10.020_bib24","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2022.10.020_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/hp.2013.02.1009","article-title":"Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay","volume":"41","author":"Wong","year":"2013","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.jtha.2022.10.020_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-2712(18)30347-0","article-title":"Contemporary laboratory monitoring of low molecular weight heparins","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jtha.2022.10.020_bib27","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2022.10.020_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A\u00a0prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.020_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017894","article-title":"The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients","volume":"98","author":"Lv","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.jtha.2022.10.020_bib30","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.clinthera.2017.07.041","article-title":"Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis","volume":"39","author":"Fan","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jtha.2022.10.020_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ajh.25820","article-title":"Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban","volume":"95","author":"Houghton","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.10.020_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1060028018811657","article-title":"Anti-Xa oral anticoagulant plasma concentration assay in real life: rivaroxaban and apixaban quantification in emergency with LMWH calibrator","volume":"53","author":"Billoir","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2022.10.020_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) Recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.020_bib34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17460441.2017.1384811","article-title":"Discovery methods of coagulation-inhibiting drugs","volume":"12","author":"Gomez-Outes","year":"2017","journal-title":"Expert Opin Drug Discov"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:33:38Z","timestamp":1761536018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622071902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1538783622071902"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in\u00a0vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}